Home/Filings/4/0001209191-10-018088
4//SEC Filing

Raser Jeffrey 4

Accession 0001209191-10-018088

CIK 0001339455other

Filed

Mar 18, 8:00 PM ET

Accepted

Mar 19, 9:52 PM ET

Size

23.2 KB

Accession

0001209191-10-018088

Insider Transaction Report

Form 4
Period: 2010-03-18
Raser Jeffrey
Senior VP, Sales and Marketing
Transactions
  • Sale

    Common Stock

    2010-03-18$8.84/sh2,100$18,57115,230 total
  • Sale

    Common Stock

    2010-03-18$6.57/sh24,500$161,05330,500 total
  • Sale

    Common Stock

    2010-03-18$7.81/sh2,400$18,75317,330 total
  • Sale

    Common Stock

    2010-03-18$9.75/sh230$2,24315,000 total
  • Sale

    Common Stock

    2010-03-18$9.73/sh1,200$11,68215,000 total
  • Sale

    Common Stock

    2010-03-18$6.56/sh7,770$50,95619,730 total
  • Exercise/Conversion

    Common Stock

    2010-03-18$1.17/sh+40,000$46,80055,000 total
  • Sale

    Common Stock

    2010-03-18$7.84/sh7,500$58,82223,000 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2010-03-1840,00060,000 total
    Exercise: $1.17Exp: 2019-07-15Common Stock (40,000 underlying)
  • Sale

    Common Stock

    2010-03-18$8.82/sh6,800$60,00416,200 total
Footnotes (10)
  • [F1]This sale was effected by the reporting person pursuant to a pre-planned selling program under Rule 10b5-1 adopted by the reporting person in 2009.
  • [F10]Not applicable.
  • [F2]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $6.25 to $7.19 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  • [F3]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.30 to $8.28 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  • [F4]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $8.46 to $9.2256 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  • [F5]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $9.735 to $9.88 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  • [F6]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $6.25 to $7.23 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  • [F7]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.34 to $8.28 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  • [F8]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $8.44 to $9.2256 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  • [F9]Fifty percent of the shares of Common Stock subject to this grant vested on March 18, 2010 and the remaining shares will vest and become exercisable upon the Company's consummation of a strategic collaboration relating to Silenor that is approved by the Board of Directors, subject to Reporting Person's continued service to the Company through such vesting date.

Issuer

Somaxon Pharmaceuticals, Inc.

CIK 0001339455

Entity typeother

Related Parties

1
  • filerCIK 0001346901

Filing Metadata

Form type
4
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 9:52 PM ET
Size
23.2 KB